<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323477</url>
  </required_header>
  <id_info>
    <org_study_id>741.STZ.2014</org_study_id>
    <nct_id>NCT02323477</nct_id>
  </id_info>
  <brief_title>Human Umbilical Cord Stroma MSC in Myocardial Infarction</brief_title>
  <acronym>HUC-HEART</acronym>
  <official_title>The Efficacy and Safety Assessment of Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction; a Phase 1/2 Clinical Trial (HUC-HEART Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turkiye Yuksek Ihtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ATIGEN-CELL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankara Yildirim BeyazÄ±t University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 1/2 clinical trial is to evaluate the efficacy and safety of
      allogeneic human umbilical cordstroma derived multipotent stem cells (hUCS-MSCs) in
      myocardial infarction (MI). All subjects will be taken into the bypass coronary surgery prior
      to the cell administration. This 2-year study comprise three independent groups, where the
      first group (n=20) will take no cells, second group will take autologous BM-MNCs (n=20), and
      third group (n=39) will be receiving allogeneic hUCS-MSCs. In all transplantations cells will
      be administered to the approximately 10 peri-infarct areas at one time. The infarct zone will
      be determined by the MR, SPECT and PET imaging. Only male subjects between 30-80 years of
      age. The efficiency of the therapy will be evaluated according to the parameters measured by
      MR, SPECT, and Echocardiography. All subject were taken into those measurements prior and 6,
      12, 18 and 24 months after the operation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventricular remodeling</measure>
    <time_frame>within one year after cell transplantation</time_frame>
    <description>Outcome measures will be determined by cardiac MR, SPECT and PET monitoring to assess the left ventricular ejection fraction (%), left ventricle end-diastolic and end-systolic volumes (mL/m2), left ventricle mass (g/m2), infarct size (%), and the thickness of the dysfunctional wall (mm).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Chronic Ischemic Cardiomyopathy</condition>
  <condition>Coronary Artery Bypass Surgery</condition>
  <arm_group>
    <arm_group_label>Allogeneic umbilical cord MSC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF&lt;%45)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous bone marrow-derived MNC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF&lt;%45)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF&lt;%45) whom will not received any further transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation</description>
    <arm_group_label>Allogeneic umbilical cord MSC group</arm_group_label>
    <arm_group_label>Autologous bone marrow-derived MNC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic hearth disease who will experience CABG

          -  %25&lt;EF&lt;%45

          -  NYHA class II-IV patients

          -  hemodynamically stable

        Exclusion Criteria:

          -  Patient's in approval

          -  Acute cardiac decompensation

          -  Acute myocardial infarction

          -  Congenital heart disease

          -  Additional surgical heart disease other than coronary artery disease

          -  Malign arrhythmia

          -  All malignancies

          -  HbA1c level &gt;%10 (86 mmol/mol) type II diabetes mellitus

          -  Severe liver dysfunction

          -  Severe COPD

          -  Coagulopathy

          -  Immunosuppressive treatment

          -  Acute hepatitis, hepatitis B, C and HIV infection

          -  Chronic liver and renal failure

          -  Collagen tissue disease

          -  Stroke

          -  TB

          -  Hematological diseases

          -  Socially and mentally disabilities
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alp Can</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alp Can, M.D., Ph.D.</last_name>
      <phone>+903125958169</phone>
      <email>alpcan@medicine.ankara.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>A. Tulga Ulus, M.D.</last_name>
      <phone>+903123054344</phone>
      <email>uluss@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara University</investigator_affiliation>
    <investigator_full_name>Alp Can</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>cellular therapy</keyword>
  <keyword>chronic ischemic heart disease</keyword>
  <keyword>phase 1/2 clinical study</keyword>
  <keyword>human umbilical cord multipotent stem cell</keyword>
  <keyword>human umbilical cord mesenchymal stem cell</keyword>
  <keyword>ischemic heart disease</keyword>
  <keyword>bone marrow mononuclear cell</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

